Mensch und Maschine Software SE

  • WKN: 658080
  • ISIN: DE0006580806
  • Land: Germany

Nachricht vom 21.10.2021 | 09:03

Mensch und Maschine Software SE presenting Q3 report 2021

DGAP-News: Mensch und Maschine Software SE / Key word(s): 9 Month figures
21.10.2021 / 09:03
The issuer is solely responsible for the content of this announcement.

M+M: Continuing on growth and record path
- Nine months EBIT +32% above pre-crisis year 2019
- Strong Q4 and new records for 2021 expected

Wessling, October 21, 2021 - Mensch und Maschine Software SE (MUM - ISIN DE0006580806), a CAD/CAM/BIM specialist company, continues on the strong growth path and achieved new Q3 and nine months records. Compared to the pre-crisis year 2019, 9M sales already gained +11%, while EBIT showed a disproportionate +32% increase.

Nine months sales climbed to EUR 193.99 mln (PY: 180.61 / +7.4%), with EUR 60.86 mln (PY: 54.93 / +11%) from M+M Software and EUR 133.13 mln (PY: 125.68 / +5.9%) from the VAR Business. The +11% increase versus 2019 was fairly equally contributed to by segments and quarters, while the comparison to 2020 is distorted by the pre-Corona record in Q1.

Operating profit EBIT grew to EUR 24.09 mln (PY: 21.76 / +11%), the highest nine month EBIT amount ever. Software contribution was EUR 15.14 mln (PY: 13.67 / +10.8%), while VAR Business achieved EUR 8.94 mln (PY: 8.09 / +10.5%). Compared to 2019, the EBIT increase was +32%, with +24% from Software and +49% from the VAR segment.

Net profit after minority shares amounting to EUR 14.39 mln (PY: 12.73 / +13%), or 85 Cents/share (PY: 76), also marked a new record level. Relative to 2019, net profit grew +30%. Operating cash flows continued to soar to EUR 30.11 mln (PY: 32.73 / 2019: 21.43) or 178 Cents/share (PY: 195 / 2019: 127), equating to about twice the net profit level.

M+M Chairman Adi Drotleff remains optimistic for 2021: 'After the pleasing 9M business, we are also expecting a strong closing quarter, resulting in new full year 2021 records both on sales and earnings level. We continue to expect for 2021 a +6-10% growth corridor to EUR 259-268 mln for sales, and we aim for a disproportionate net profit increase by 12-21% (or +26-36% vs 2019) to 125-135 Cents per share and a 115-120 Cents (PY: 100 / 2019: 85) dividend.'

 


21.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021